Prostate cancer remains the most common cancer among men. About 40% of men with prostate cancer are diagnosed with intermediate risk disease. Radiation therapy with hormonal therapy has been associated with favorable sexual function compared with other treatments. However, many men still experience erectile dysfunction.
INTREPId (INTermediate Risk Erection PreservatIon Trial) is an innovative study that aims to maximize the effectiveness of prostate cancer treatment while preserving erectile function. Study participants will receive either a new hormonal therapy or standard hormonal therapy in combination with their radiation therapy.
The new form of hormonal therapy, called darolutamide, has proved effective in advanced forms of prostate cancer. The INTREPId study will explore its effect on intermediate risk prostate cancer and whether it preserves erectile function better than standard hormonal therapy.